Matthew (Matt) Young, Ph.D.

Dr. Matthew Young is a Program Director for gastrointestinal cancers at the Cancer Biomarkers Research Group (CBRG), Division of Cancer Prevention, the National Cancer Institute. Dr. Young is well recognized for his earlier studies in the Laboratory of Cancer Prevention at the NCI where his research was focused on gene regulation of tumor promotion, mouse models for cancer prevention and dietary intervention to prevent colon cancer.

In the CBRG, Dr. Young is a Program Officer for the Early Detection Research Network (EDRN) Gastrointestinal (GI) Cancers collaborative group. His portfolio includes grant awards for colorectal and esophageal cancer. Dr. Young also participates in the management and oversight of the Pancreatic Cancer Detection Consortium (PCDC) and oversees the Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection.  Dr. Young is the lead Program Officer for the Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection and provides programmatic leadership for developing standards for liquid biopsy. Dr. Young manages an Interagency Agreement with the National Institute of Standards and Technology which in focused on developing reference material for liquid biopsy assays.